


Arbutus Biopharma Corporation (Thu, Apr 25, 2024)

Sell candidate since Apr 25, 2024

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **-1.40**
#10554/ 30099

Trend: Buy
MV Long: Sell
MV Short: Sell
Pivot: Sell
Volume: Sell
MACD: Sell

Tech commentaries:

The **Arbutus Biopharma Corporation** stock price fell by **-1.09%** on the last day (Thursday, 25th Apr 2024) from **\$2.75** to **\$2.72**. During the last trading day the stock fluctuated **2.43%** from a day low at **\$2.68** to a day high of **\$2.75**. The price has fallen in 7 of the last 10 days and is down by **-10.23%** for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by **-21 thousand** shares and in total, **318** thousand shares were bought and sold for approximately **\$864.87** thousand.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise **7.89%** during the next 3 months and, with a 90% probability hold a price between **\$2.77** and **\$3.42** at the end of this 3-month period.

There are few to no technical positive signals at the moment. The **Arbutus Biopharma Corporation** stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at **\$2.73** and **\$2.73**. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on **Friday, April 05, 2024**, and so far it has fallen **-12.82%**. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

On the downside, the stock finds support just below today's level from accumulated volume at **\$2.54** and **\$2.49**. On the upside the stock meets some resistance from accumulated volume at **\$2.92**, **\$3.00** and **\$3.12**.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved **\$0.0650** between high and low, or **2.43%**. For the last week the stock has had daily average volatility of **3.65%**.

The Arbutus Biopharma Corporation stock holds several negative signals and despite the positive trend, we believe **Arbutus Biopharma Corporation** will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Sell candidate.

Risk: High

Evaluation: Sell Candidate

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.